13位密码子突变与爱必妥相关信息.pdf

Published Ahead of Print on June 25, 2012 as 10.1200/JCO.2012.42.2592 The latest version is at /cgi/doi/10.1200/JCO.2012.42.2592 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab Sabine Tejpar, Ilhan Celik, Michael Schlichting, Ute Sartorius, Carsten Bokemeyer, and Eric Van Cutsem Sabine Tejpar and Eric Van Cutsem, A B S T R A C T University Hospital Gasthuisberg, Leuven, Belgium; Ilhan Celik, Michael Schlichting, and Ute Sartorius, Merck Purpose KGaA, Darmstadt; and Carsten Boke- We investigated in the first-line setting our previous finding that patients with chemorefractory meyer, University Medical Center KRAS G13D–mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment. Hamburg-Eppendorf, Hamburg, Methods Germany. Associations between tumor KRAS mutation status (wild-type, G13D, G12V, or other mutations) Submitted February 16, 2012; accepted and progression-free survival (PFS), survival, and response were investigated in pooled data from May 8, 2012; published online ahead of 1,378 evaluable patients from the CRYSTAL and OPUS studies. Multivariate analysis correcting for print at on June 25, 2012. differences in baseline prognostic factors w